Posted by Michael Wonder on 04 Aug 2018
ICER final report highlights limitations in evidence on long-term safety and effectiveness of elagolix for endometriosis, discusses options for insurance coverage criteria
3 August 2018 - Because elagolix’s price aligns with clinical benefit only when compared to no other treatment, insurers may first encourage patients to try oral contraceptives and leuprorelin acetate before progressing to a new treatment that has an unknown long-term safety profile.
The Institute for Clinical and Economic Review today released a Final Evidence Report and Report-at-a-Glance on elagolix (OrilissaT, AbbVie), for the management of moderate to severe pain associated with endometriosis.
ICER’s report was reviewed at a July 2018 public meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC), one of ICER’s three independent evidence appraisal committees.
